GINSENOSIDE RB3

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C53H90O22
Molecular Weight	1079.2685
Optical Activity	UNSPECIFIED
Defined Stereocenters	29 / 29
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@@]1(CC[C@]2(C)[C@]1([H])[C@H](O)C[C@]3([H])[C@@]4(C)CC[C@H](O[C@]5([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O[C@]6([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O)C(C)(C)[C@]4([H])CC[C@@]23C)[C@](C)(CCC=C(C)C)O[C@@H]7O[C@H](CO[C@@H]8OC[C@@H](O)[C@H](O)[C@H]8O)[C@@H](O)[C@H](O)[C@H]7O

InChI

InChIKey=NODILNFGTFIURN-USYOXQFSSA-N

InChI=1S/C53H90O22/c1-23(2)10-9-14-53(8,75-47-43(67)39(63)37(61)29(72-47)22-69-45-41(65)34(58)26(57)21-68-45)24-11-16-52(7)33(24)25(56)18-31-50(5)15-13-32(49(3,4)30(50)12-17-51(31,52)6)73-48-44(40(64)36(60)28(20-55)71-48)74-46-42(66)38(62)35(59)27(19-54)70-46/h10,24-48,54-67H,9,11-22H2,1-8H3/t24-,25+,26+,27+,28+,29+,30-,31+,32-,33-,34-,35+,36+,37+,38-,39-,40-,41+,42+,43+,44+,45-,46-,47-,48-,50-,51+,52+,53-/m0/s1

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21948936
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/22741793 | https://www.ncbi.nlm.nih.gov/pubmed/21158074 | https://www.ncbi.nlm.nih.gov/pubmed/21591990 | https://www.ncbi.nlm.nih.gov/pubmed/19655413 | https://www.ncbi.nlm.nih.gov/pubmed/20969942 | https://www.ncbi.nlm.nih.gov/pubmed/20662827 | https://www.ncbi.nlm.nih.gov/pubmed/25371727 | https://www.ncbi.nlm.nih.gov/pubmed/25084093 | https://www.ncbi.nlm.nih.gov/pubmed/26287932 | https://www.ncbi.nlm.nih.gov/pubmed/25577870 | https://www.ncbi.nlm.nih.gov/pubmed/24571453

Ginsenoside Rb3 is a protopanaxadiol ginsenoside that can be isolated from several different Panax species. Ginsenoside Rb3 exerts antidepressant and antidiabetic activities as well as cardio- and neroprotective action in ischemic tissue injury in animal models. Ginsenoside Rb3 inhibits apoptosis and cell proliferation, in addition it demonstrates antiaxidant properties. Ginsenoside Rb3 may modulate activity of GABA-A and NMDA receptors.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Potency
Oxidative Stress 160 Target ID: WP408 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26287932 \| https://www.ncbi.nlm.nih.gov/pubmed/25577870 \| https://www.ncbi.nlm.nih.gov/pubmed/24571453	Inhibitor 8297
apoptotic process 48 Target ID: GO:0006915 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25371727 \| https://www.ncbi.nlm.nih.gov/pubmed/25084093	Inhibitor 8297
NF-kappa B signaling pathway 84 Target ID: map04064 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25210319 \| https://www.ncbi.nlm.nih.gov/pubmed/25084093	Inhibitor 8297	8.2 µM [IC50]
cell proliferation 28 Target ID: GO:0008283 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20662827	Inhibitor 8297
Glutamate [NMDA] receptor 125 Target ID: CHEMBL2094124 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19655413	Inhibitor 8297
GABA-A receptor; anion channel 202 Target ID: CHEMBL2093872 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20969942	Activator 1430
Glycine receptor (alpha-1/beta) 15 Target ID: CHEMBL2363052 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15777757	Inhibitor 8297
Pregnane X receptor 35 Target ID: CHEMBL3401 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23600156	Inhibitor 8297

Conditions

Condition	Modality	Highest Phase	Product
Diabetes mellitus 91 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22741793	Primary	Preclinical	Unknown Approved Use Unknown
Hypertension 567 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24571453	Primary	Preclinical	Unknown Approved Use Unknown
Depression 235 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21948936 https://www.ncbi.nlm.nih.gov/pubmed/26528894	Primary	Preclinical	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Ginsenoside Rb3 protects cardiomyocytes against ischemia-reperfusion injury via the inhibition of JNK-mediated NF-κB pathway: a mouse cardiomyocyte model.	2014	25084093

Sample Use Guides

In Vivo Use Guide

myocardial ischemia-reperfusion injury in rats: 5-20 mg/kg. antidepressant-like effects in rodent models: 30-150 mg/kg.

Route of Administration: Oral

In Vitro Use Guide

Ginsenosides Rb3 (0.1-10 uM) inhibits with IC50 8.2 uM tumor necrosis factor-α (TNF)-induced nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) luciferase reporter activity using a human kidney 293T cell-based assay. In vitro, at concentrations of 100 and 200 µM, ginsenoside Rb3 increased glucose consumption in C2C12 myotubes by 76.83% and 97.20%, respectively, as compared to the control group.

Name

Type

Language

GINSENOSIDE RB3

Common Name

English

.BETA.-D-GLUCOPYRANOSIDE, (3.BETA.,12.BETA.)-3-((2-O-.BETA.-D-GLUCOPYRANOSYL-.BETA.-D-GLUCOPYRANOSYL)OXY)-12-HYDROXYDAMMAR-24-EN-20-YL 6-O-.BETA.-D-XYLOPYRANOSYL-

Systematic Name

English

GYPENOSIDE IV

Common Name

English

Code System Code Type Description

EPA CompTox

DTXSID601317092